JP2007297414A - 標的された部位特異的薬物送達組成物およびその使用 - Google Patents
標的された部位特異的薬物送達組成物およびその使用 Download PDFInfo
- Publication number
- JP2007297414A JP2007297414A JP2007215329A JP2007215329A JP2007297414A JP 2007297414 A JP2007297414 A JP 2007297414A JP 2007215329 A JP2007215329 A JP 2007215329A JP 2007215329 A JP2007215329 A JP 2007215329A JP 2007297414 A JP2007297414 A JP 2007297414A
- Authority
- JP
- Japan
- Prior art keywords
- microbubbles
- albumin
- odn
- site
- ultrasound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61549596A | 1996-03-12 | 1996-03-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53279697A Division JP4774135B2 (ja) | 1996-03-12 | 1997-03-12 | 標的された部位特異的薬物送達組成物およびその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007297414A true JP2007297414A (ja) | 2007-11-15 |
Family
ID=24465630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007215329A Withdrawn JP2007297414A (ja) | 1996-03-12 | 2007-08-21 | 標的された部位特異的薬物送達組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0888054B1 (de) |
| JP (1) | JP2007297414A (de) |
| AT (1) | ATE248511T1 (de) |
| AU (1) | AU725693B2 (de) |
| CA (1) | CA2248158A1 (de) |
| DE (1) | DE69724599T2 (de) |
| WO (1) | WO1997033474A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
| EP0991427A2 (de) * | 1996-10-28 | 2000-04-12 | Marsden, John Christopher | Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen mitteln |
| AU733495B2 (en) | 1996-10-28 | 2001-05-17 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| WO1998018501A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
| CA2337361C (en) * | 1998-07-13 | 2010-11-16 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
| GB9917416D0 (de) * | 1999-07-23 | 1999-09-22 | Univ Ulster | |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| DE10108798A1 (de) * | 2001-02-19 | 2002-09-26 | Laser & Med Tech Gmbh | Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo |
| JPWO2003043663A1 (ja) * | 2001-11-22 | 2005-03-10 | アンジェスMg株式会社 | 臓器移植における拒絶反応を抑制する組成物およびその使用方法 |
| WO2003080123A1 (fr) * | 2002-03-22 | 2003-10-02 | Anges Mg, Inc. | Compositions delivrant un medicament biologiquement actif, et procede d'utilisation |
| US8012118B2 (en) | 2006-03-08 | 2011-09-06 | Fresenius Medical Care Holdings, Inc. | Artificial kidney dialysis system |
| US8715221B2 (en) | 2006-03-08 | 2014-05-06 | Fresenius Medical Care Holdings, Inc. | Wearable kidney |
| CA2661221C (en) | 2006-08-24 | 2014-03-18 | Fresenius Medical Care Holdings, Inc. | Device for removing fluid from blood in a patient |
| US8454937B2 (en) | 2006-09-12 | 2013-06-04 | Temple University—Of The Commonwealth System of High Education | Method and composition for the site-selective delivery using viruses encapsulated in microbubbles |
| AU2009320025B2 (en) | 2008-11-03 | 2013-02-28 | Fresenius Medical Care Holdings, Inc. | Portable peritoneal dialysis system |
| US20130072854A1 (en) * | 2011-09-19 | 2013-03-21 | General Electric Company | Microbubble complexes and methods of use |
| WO2014117232A1 (pt) * | 2013-02-04 | 2014-08-07 | Farret Neto Abdo | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
| WO2016168993A1 (en) | 2015-04-22 | 2016-10-27 | Innolife Co., Ltd. | Methods of tissue repair and regeneration |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2068334C (en) * | 1990-10-05 | 1996-09-03 | Bracco International B.V. | Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography |
| EP0732106A3 (de) * | 1991-03-22 | 2003-04-09 | Katsuro Tachibana | Mikrobläschen enthaltende Verstärker zur Ultraschalltherapie von Erkrankungen |
| US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
| JP2001502349A (ja) * | 1996-10-21 | 2001-02-20 | ニユコメド・イメージング・アクシエセルカペト | 造影剤におけるまたはこれに関する改良 |
-
1997
- 1997-03-12 CA CA002248158A patent/CA2248158A1/en not_active Abandoned
- 1997-03-12 DE DE69724599T patent/DE69724599T2/de not_active Expired - Lifetime
- 1997-03-12 EP EP97915020A patent/EP0888054B1/de not_active Expired - Lifetime
- 1997-03-12 AU AU22071/97A patent/AU725693B2/en not_active Expired
- 1997-03-12 AT AT97915020T patent/ATE248511T1/de active
- 1997-03-12 WO PCT/US1997/003876 patent/WO1997033474A1/en not_active Ceased
-
2007
- 2007-08-21 JP JP2007215329A patent/JP2007297414A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0888054A1 (de) | 1999-01-07 |
| AU2207197A (en) | 1997-10-01 |
| AU725693B2 (en) | 2000-10-19 |
| EP0888054B1 (de) | 2003-09-03 |
| ATE248511T1 (de) | 2003-09-15 |
| CA2248158A1 (en) | 1997-09-18 |
| WO1997033474A1 (en) | 1997-09-18 |
| DE69724599T2 (de) | 2004-08-05 |
| DE69724599D1 (de) | 2003-10-09 |
| EP0888054A4 (de) | 1999-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007297414A (ja) | 標的された部位特異的薬物送達組成物およびその使用 | |
| US5849727A (en) | Compositions and methods for altering the biodistribution of biological agents | |
| US6245747B1 (en) | Targeted site specific antisense oligodeoxynucleotide delivery method | |
| JP5049958B2 (ja) | 超音波媒介デリバリー用ガス充填マイクロカプセル含有医薬組成物 | |
| Porter et al. | Interaction of diagnostic ultrasound with synthetic oligonucleotide‐labeled perfluorocarbon‐exposed sonicated dextrose albumin microbubbles. | |
| EP1046394A2 (de) | Neue Zusammensetzungen zur Verwendung bei der Verabreichung von Verbindungen in das Zellinnere | |
| CA2337361C (en) | Targeted site specific drug delivery compositions and method of use | |
| JP2001503407A (ja) | 改良された診断/治療用薬剤 | |
| JP2001511765A (ja) | 改良された診断/治療用薬剤 | |
| AU2012311659A1 (en) | Microbubble complexes and methods of use | |
| JP4774135B2 (ja) | 標的された部位特異的薬物送達組成物およびその使用 | |
| KR100649035B1 (ko) | 표적화된 부위특이적 약물 송달 조성물 및 사용방법 | |
| JP2001502719A (ja) | 改良された診断/治療用薬剤 | |
| AU7825001A (en) | Methods for delivering compounds into a cell | |
| HK1251462B (zh) | 微泡复合物及使用方法 | |
| HK1200362B (en) | Microbubble complexes and methods of use | |
| HRP970328A2 (en) | Methods for delivering compounds into a cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070821 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110118 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110520 |